New PINNACLE Measures

The below measures for PINNACLE will be added as **new measures** to the outcomes reporting starting with Version 2.0.

Measure Topic	Steward	Measure Name	Measure Description	Rationale for Adding New Measures
Obesity	CMS	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	Percentage of patients, aged 18 years and older, with a BMI documented during the current encounter or during the previous twelve months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous twelve months of the current encounter Normal Parameters: Age 18 years and older BMI ≥ 18.5 and < 25 kg/m2	
Obesity	ACC	BMI stratification	Stratification of patients within the practice that have a documented BMI: (Results stratified by ethnicity and gender)	By performing regular assessments of lifestyle factors providers can identify
Obesity	ACC	Weight reduction/management Plan of care patients with metabolic syndrome	Weight reduction/management plan of care for patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)	patients at risk ultimately lowering the chances of associated medical comorbidities and care costs.
Obesity	NCQA	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit and who had evidence of the following during the measurement period. Three rates are reported. Percentage of patients with height, weight, and body mass index (BMI) percentile documentation - Percentage of patients with counseling for nutrition - Percentage of patients with counseling for physical activity	
Preventive Care & Screening	РСРІ	Preventive Care and Screening: Unhealthy Alcohol Use: Screening and Brief Counseling	Percentage of patients aged 18 years and older, who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol user	This measure was selected by the work group alcohol screening is important in preventing chronic illness and death.

Measure	Steward	Measure Name	Measure Description	Rationale for Adding New Measures
Торіс				
Preventive	PCPI	Influenza Immunization	Percentage of patients, aged 6 months and older, seen for a	This measure was selected by the work group
Care &			visit between October 1 and March 31, who received an	since immunization screening for both the
Screening			influenza immunization OR who reported previous receipt of an	pediatric and adult population is important in
			influenza immunization	preventing chronic illness and death.

Retired PINNACLE Measures

The below measures for PINNACLE be **retired** as of the first outcomes report of Version 2.0

Measure ID	Measure Name	Measure Description	Rationale for Retirement
PINN 100	CAD: Blood Pressure Control	Percentage of patients aged ≥18 years with a diagnosis of coronary artery disease seen within a 12-month period who have a blood pressure < 140/90 mm Hg, OR who have a blood pressure ≥140/90 mm Hg and were prescribed ≥2 antihypertensive medications during the most recent office visit	Measures changed to reflect the 2017
PINN 100-1	Coronary Artery Disease (CAD): Sub-Measure 1-Blood Pressure Control	Percentage of patients aged ≥18 years with a diagnosis of coronary artery disease seen within a 12-month period who have a blood pressure < 140/90 mm Hg during the most recent office visit	ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. See measure numbers PINN 121, 122,123
PINN 100-2	Coronary Artery Disease (CAD): Sub-Measure 2 Antihypertensive Medication Utilization	Percentage of patients aged ≥18 years with a diagnosis of coronary artery disease seen within a 12-month period who have a blood pressure ≥140/90 mm Hg and were prescribed ≥2 antihypertensive medications during the most recent office visit	
PINN 104	Tobacco Cessation and Intervention	Percentage of patients aged ≥18 years with a diagnosis of coronary artery disease seen within a 12-month period who were screened for tobacco use AND received tobacco-cessation counseling if identified as tobacco users	PINN Measure is specified for patients with CAD only. This measure is retired as there is already a smoking cessation measure in an 'all patient' population (i.e. not CAD only) which can be reported in both PINN and DCR (PINN 185).

Measure ID	Measure Name	Measure Description	Rationale for Retirement
PINN 120	Hypertension: Blood Pressure Management	Percentage of patients aged ≥18 years with a diagnosis of hypertension seen within a 12-month period who have a blood pressure <140/90 mm Hg, OR who have a blood pressure ≥140/90 mm Hg and were prescribed ≥2 antihypertensive medications during their most recent office visit	Measures changed to reflect the 2017
PINN 120-1	Hypertension (HTN): Sub- Measure 1 Blood Pressure Control	Percentage of patients aged ≥18 years with a diagnosis of hypertension seen within a 12-month period who have a blood pressure <140/90 mm Hg	ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. See measure numbers PINN 121, 122,123
PINN 120-2	Hypertension (HTN): Sub- Measure 2 Anti-hypertension Medication Utilization	Percentage of patients aged ≥18 years with a diagnosis of hypertension seen within a 12-month period who have a blood pressure ≥140/90 mm Hg and were prescribed ≥2 antihypertensive medications during their most recent office visit	See measure numbers pinn 121, 122,125
PINN 150-1	Heart Failure: ACE Inhibitor, ARB, or ARNI therapy for LV systolic dysfunction	Percentage of patients aged ≥ 18 y with a diagnosis of HF with a current or prior LVEF of $\leq 40\%$ (moderate/severe dysfunction) who were prescribed ACE inhibitor, ARB, or ARNI therapy within a 12-month period when seen in the outpatient setting	PINN Measure 150-1 and 150-2 are being retired because they
PINN 150-2	Heart Failure LVSD ARNI therapy	Percentage of patients aged ≥18 y with a diagnosis of HF with a current or prior NYHA Class II or III or prior LVEF ≤ 40% (moderate/severe dysfunction) who were prescribed ARNI (valsartan/sacubitril) therapy with a 12-month period when seen in the outpatient setting	have the same measure focus as PINN 145
PINN 162	(Test Metric) Atrial Fibrillation and Atrial Flutter: CHA2DS2–VASc Score Risk Score Documented	Percent of patients, age 18 and older, with nonvalvular atrial fibrillation or atrial flutter for whom a CHA2DS2- VASc risk score is documented.	Measure is being retired because it was a test metric to include the latest atrial fibrillation stroke risk assessment tool. PINN 160 has the same measure intent and therefore 162 can be retired as it is duplicative

Modified PINNACLE Measures

The below measures for PINNACLE will be **modified** starting with Version 2.0

Measure ID	Steward	Measure Name	Measure Description	Rationale for Modification
PINN 145	AMA- PCPI/ACCF/AHA	Heart Failure: Angiotensin- Converting Enzyme Inhibitor or ARB	Percentage of patients, aged ≥18 years, with a diagnosis of HF with a current or prior LVEF of <40% who were prescribed ACE inhibitor or ARB therapy either within a 12-mo period when seen in the outpatient setting or at hospital discharge	A numerator note will be added that will also include ARNI class of medications
PINN 146	AMA- PCPI/ACCF/AHA	Heart Failure: Counseling about ICD Implementation for LVSD	Percentage of patients, aged \geq 18 years, with a diagnosis of HF with current LVEF \leq 35% despite ACE inhibitor/ARB and betablocker therapy for at least 3 months who were counseled about ICD implantation as a treatment option for the prophylaxis of sudden death	ICD Counseling measure has been modified to improve feasibility.

Unmodified PINNACLE Measures

The below measures for PINNACLE remain the same and will be included in first outcomes report of Version 2.0

Measure ID	Measure Name	Measure Description
PINN 14	Advance Care Plan	Percentage of patients, aged 65 years and older, who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan.
PINN 36	CAD Lipid Control	Percentage of patients, aged \geq 18 years, with a diagnosis of coronary artery disease with a prescription of a statin.
PINN 102	CAD: Symptom and Activity Assessment	Percentage of patients, aged ≥ 18 years, with a diagnosis of coronary artery disease seen within a 12-month period for whom there are documented results of an evaluation of level of activity AND an evaluation of presence or absence of angina symptoms (includes assessment of angina equivalents) in the medical record
PINN 103	CAD: Symptom Management	Percentage of patients, aged ≥ 18 years, with a diagnosis of coronary artery disease seen within a 12-month period and with results of an evaluation of level of activity, AND with an evaluation of presence or absence of anginal symptoms‡, with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of angina symptoms, OR evaluation of level of activity and symptoms includes report of anginal symptoms, and a plan of care is documented to achieve control of anginal symptoms)

Measure ID	Measure Name	Measure Description
PINN 103-1	Coronary Artery Disease (CAD): Sub-Measure 1- Symptom Management	Percentage of patients, aged ≥ 18 years, with a diagnosis of coronary artery disease seen within a 12-month period and with results of an evaluation of level of activity, AND with an evaluation of presence or absence of anginal symptoms [‡] , with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of angina symptoms)
PINN 103-2	Coronary Artery Disease (CAD): Sub-Measure 2-Plan of Care for Anginal Symptom Control	Percentage of patients, aged ≥ 18 years, with a diagnosis of coronary artery disease seen within a 12-month period and evaluation of level of activity and symptoms includes report of anginal symptoms, AND a plan of care is documented to achieve control of anginal symptoms (>= 2 anti-anginal medications prescribed OR Referral for consideration for coronary revascularization or referral for additional evaluation or treatment of angina symptoms
PINN 105	CAD: Antiplatelet Therapy	Percentage of patients, aged ≥ 18 years, with a diagnosis of coronary artery disease seen within a 12-month period who were prescribed aspirin or clopidogrel.
PINN 106	CAD: Beta-Blocker Therapy	Percentage of patients, aged ≥18 years, with a diagnosis of coronary artery disease seen within a 12-month period who also have prior myocardial infarction or a current or prior LVEF <40% who were prescribed beta-blocker therapy.
PINN 107	CAD: Ace inhibitor or Ace Receptor Block Therapy	Percentage of patients, aged 18 years and older, with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes or a current or prior LVEF <40% who were prescribed ACE inhibitor or ARB therapy
PINN 108	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	Percentage of patients evaluated in an outpatient setting who within the previous 12 months have experienced an acute myocardial infarction, coronary artery bypass graft surgery, PCI, cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina and have not already participated in an early outpatient CR or secondary prevention program for the qualifying event/diagnosis and are referred to such a program
PINN 109	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk	Percentage of patients, 18-75 years old, with CAD who were offered moderate-to-high intensity statin

Measure ID	Measure Name	Measure Description
PINN 140	Heart Failure: LVEF Assessment	Percentage of patients, aged ≥ 18 years, with a diagnosis of heart failure for whom the quantitative or qualitative results of a recent or prior (any time in the past) left ventricular ejection fraction assessment is documented within a 12-month period
PINN 141	Heart Failure: Symptom and Activity Assessment	Percentage of patient visits for those patients, aged ≥18 years, with a diagnosis of heart failure with quantitative results of an evaluation of both current level of activity and clinical symptoms documented.
PINN 142	Heart Failure: Symptom Management	Percentage of patient visits for those patients, aged ≥18 years, with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND clinical symptoms documented in which patient symptoms have improved or remained consistent with treatment goals since last assessment OR patient symptoms have demonstrated clinically important deterioration since last assessment with a documented plan of care.
PINN 142-1	Heart Failure: Symptom Management (Sub-Measure 1) - Symptoms Improved/Stable	Percentage of patient visits for those patients, aged ≥18 years, with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND clinical symptoms documented in which patient symptoms have improved or remained consistent with treatment goals since last assessment
PINN 142-2	Heart Failure: Symptom Management (Sub-Measure 2) Symptom Management (Symptoms Declined with Plan)	Percentage of patient visits for those patients, aged ≥18 years, with a diagnosis of HF and with quantitative results of an evaluation of both level of activity AND patient symptoms have demonstrated clinically important deterioration since last assessment with a documented plan of care.
PINN 143	Heart Failure: Patient Self Education	Percentage of patients, aged \geq 18 years, with a diagnosis of heart failure who were provided with self-care education on \geq 3 elements of education during \geq 1 visit within a 12-month period
PINN 144	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction EF<40%	Percentage of patients, aged ≥18 years, with a diagnosis of heart failure with a current or prior LVEF of < 40% who were prescribed beta-blocker therapy with bisoprolol, carvedilol, or sustained-release metoprolol succinate
PINN 147	Heart Failure: Etiology	Percentage of patients, aged ≥18 years, with a diagnosis of HF with qualitative etiology of HF has been identified and documented within a 12-month period when seen in the outpatient setting

Measure ID	Measure Name	Measure Description
PINN 148	Heart Failure: Serum Electrolyte Level Assessment	Percentage of patients, aged ≥ 18 years, with a diagnosis of HF with quantitative laboratory evaluation of serum sodium and potassium ordered and qualitative results documented within a 12-month period when seen in the outpatient setting
PINN 149	Heart Failure: Natriuretic Peptide Biomarker Assessment	The percentage of patients aged >= 18 YO for whom laboratory evaluation of B-type Natriuretic Peptide (BNP or N-terminal pro- B Natriuretic Peptide (NT-proBNP) have been ordered and quantitative results documented within a 12-month period when seen in the outpatient setting
PINN 151	(Test Metric) Heart Failure: Hydralazine and Isosorbide Dinitrate Therapy for African Americans with Left Ventricular Systolic Dysfunction	Percentage of Black/African American patients aged ≥18 y with a diagnosis of HF, a current or prior NYHA Class II or III, a LVEF <= 40% (moderate/severe dysfunction), and who have been taking ACE inhibitors and Beta blockers for at least 3 months who were prescribed ARNI therapy
PINN 160	Atrial Fibrillation and Atrial Flutter: Assessment of Thromboembolic Risk Factors	Percentage of patients, age ≥ 18 years, with nonvalvular atrial fibrillation or atrial flutter for whom a CHA2DS2-VASc risk score is documented.
PINN 161	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	Chronic Anticoagulation Therapy: Percentage of patients aged ≥18 years with non-valvular AF or atrial flutter at high risk for thromboembolism, according to CHADS2 risk stratification, who were prescribed warfarin or another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism
PINN 170	Peripheral Artery Disease: Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk	Percentage of patients age 18 to 75 years with a diagnosis of Peripheral Artery Disease (PAD) who had a moderate-or high intensity statin
PINN 181	Documentation of Current Medications in the Medical Record	Percentage of visits for patients, aged 18 years and older, for which the eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter.
PINN 185	Tobacco Use: Screening and Cessation Intervention	Percentage of patients, aged 18 years and older, who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user.

Measure ID	Measure Name	Measure Description
PINN 109	Diabetes & Coronary Artery Disease: Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk [Test Metric]	Percentage of patients age 18 to 75 years with a diagnosis of Coronary Artery Disease (CAD) who had a moderate or high intensity statin
PINN 121	Hypertension: Blood Pressure Treatment and Control for High Risk Patients	Proportion of adults, ≥ 18 years of age, with both hypertension and a ≥ 10% CVD risk OR high-risk diagnosis (i.e. ASCVD, chronic kidney disease, diabetes) who were prescribed antihypertensive medication or who had adequately controlled blood pressure
PINN 122	Hypertension: Blood Pressure Treatment and Control for Stage 2 Hypertensive Patients	Proportion of adults, ≥ 18 years of age, with hypertension who were prescribed antihypertensive medications or who had adequately controlled blood pressure
PINN 123	Hypertension Treatment (Stage 1 or Stage 2)	Proportion of adults, ≥ 18 years of age, with a diagnosis of hypertension who had adequately controlled blood pressure